Results 31 to 40 of about 16,960 (244)

A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers

European Heart Journal, 2023
Remco de Brouwer , Wouter P. te Rijdt , Edgar T. Hoorntje , Ahmad Amin, Folkert W. Asselbergs , Moniek G.P.J. Cox, Jeroen F. van der Heijden, Hans Hillege , Jacco C. Karper, Belend Mahmoud, Peter van der Meer, Anton Oomen, Anneline S.J.M.
R. de Brouwer, W. T. te Rijdt, E. Hoorntje, A. Amin, F. Asselbergs, M. Cox, J. F. van der Heijden, H. Hillege, J. Karper, B. Mahmoud, P. van der Meer, A. Oomen, A. S. T. te Riele, H. Silljé, H. Tan, J. V. van Tintelen, D. V. van Veldhuisen, B. Westenbrink, A. Wiesfeld, T. Willems, P. A. van der Zwaag, A. Wilde, R. D. de Boer, M. P. van den Berg   +23 more
semanticscholar   +1 more source

Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. [PDF]

PLoS ONE, 2011
Reduction of proteinuria and blood pressure (BP) with blockers of the renin-angiotensin system (RAS) impairs the progression of chronic kidney disease (CKD).
Lene Boesby, Thomas Elung-Jensen, Tobias Wirenfeldt Klausen, Svend Strandgaard, Anne-Lise Kamper   +4 more
doaj   +1 more source

Clinical Determinants and Prognostic Implications of Renin and Aldosterone in Patients with Symptomatic Heart Failure [PDF]

, 2020
Aims Activation of the renin-angiotensin-aldosterone system plays an important role in the pathophysiology of heart failure (HF) and has been associated with poor prognosis.
Anker, Stefan D., Dickstein, Kenneth, Duarte, Kevin, Ferreira, Joao Pedro, Girerd, Nicolas, Kobayashi, Masatake, Lamiral, Zohra, Lang, Chim C., Metra, Macro, Ng, Leong L., Preud'homme, Gregoire, Rossignol, Patrick, Samani, Nilesh J., Stienen, Susan, ter Maaten, Jozine M., van Veldhuisen, Dirk J., Voors, Adriaan A., Zannad, Faiez   +17 more
core   +5 more sources

Eplerenone Implantation Improved Adipose Dysfunction Averting RAAS Activation and Cell Division

Frontiers in Endocrinology, 2020
Introduction: Mineralocorticoid receptor (MR) activation within adipose tissue, triggers inflammation and metabolic syndrome development. The pharmacological blockade of MR provides beneficial effects for adipose tissue. Our study evaluates the impact of
Andrea Vecchiola, Andrea Vecchiola, Cristóbal A. Fuentes, Isidora Solar, Carlos F. Lagos, Maria Cecilia Opazo, Maria Cecilia Opazo, Natalia Muñoz-Durango, Natalia Muñoz-Durango, Claudia A. Riedel, Claudia A. Riedel, Gareth I. Owen, Gareth I. Owen, Alexis M. Kalergis, Alexis M. Kalergis, Alexis M. Kalergis, Carlos E. Fardella, Carlos E. Fardella, Carlos E. Fardella   +18 more
doaj   +1 more source

The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury

Frontiers in Pharmacology, 2021
The therapeutic indices (TIs) and efficacy of the non-steroidal mineralocorticoid receptor antagonist (MRA) KBP-5074 and steroidal MRA eplerenone were evaluated in a uninephrectomized Sprague Dawley rat model of aldosterone-mediated renal disease. In two
Frédéric Jaisser, Xiaojuan Tan, Shuangshuang Chi, Jinrong Liu, Ping Wang, Mark Bush, Vincent Benn, Y. Fred Yang, Jay Zhang   +8 more
doaj   +1 more source

Real world comparison of spironolactone and eplerenone in patients with heart failure.

European journal of internal medicine, 2022
AIMS In the absence of previous direct comparative studies, we aimed to evaluate the effectiveness of spironolactone and eplerenone in patients with heart failure and reduced ejection fraction (HFrEF) in a real-world clinical setting.
P. Pardo-Martínez, E. Barge-Caballero, A. Bouzas-Mosquera, G. Barge-Caballero, D. Couto-Mallón, M. Paniagua-Martin, M. Sagastagoitia-Fornie, Ó. Prada‐Delgado, J. Muñiz, Luis Almenar-Bonet, J. Vazquez-Rodriguez, M. Crespo-Leiro   +11 more
semanticscholar   +1 more source

Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm [PDF]

, 2016
Many conditions culminate in heart failure (HF), a multi-organ systemic syndrome with an intrinsically poor prognosis. Pharmacotherapeutic agents that correct neurohormonal dysregulation and haemodynamic instability have occupied the forefront of ...
Abozguia, AIRE Study Group, Alexander, Alexander, Alexander, Alexander, Ashrafian, Bailey, Bailey, Basu, Beadle, Braunwald, Brown, Burgoyne, Chaitman, Chatterjee, Chung, CIBIS-II Study Group, Cleland, Clerc, Cohn, Cohn, Cohn, CONSENSUS Trial Study Group, Conway, Cook, Dai, Digitalis Investigation Group, Doenst, Dzau, Dzau, Faris, Flather, Follath, Foster, Fox, Fox, Fragasso, Furberg, Gheorghiade, Gladwin, Goffart, Granger, Greenberg, Guazzi, Guazzi, Heymans, Hobbs, Holubarsch, Horowitz, Horowitz, Kantor, Kapil, Kato, Kennedy, Kennedy, Kostis, Larsen, Lee, Lopaschuk, Luiken, Lundberg, Maher, Maier, Mancini, Mann, Mann, Massie, Mccormack, Mcdowell, Mcmurray, Mcmurray, Merit-Hf Study Group, Munzel, Munzel, Neglia, Neubauer, Ormerod, Packer, Packer, Paul, Pawson, Pfeffer, Pfeffer, Pitt, Pitt, Rathore, Rauchhaus, Redfield, Rona, Sack, Sarraf, Schmidt-Schweda, Schrauwen, Schwarz, Shah, Shah, Siddiqi, Singh, SOLVD Investigators, Stanley, Swedberg, Szwed, Taylor, Teerlink, Tilemann, Torre-Amione, Totzeck, Turcani, Unger, Van Der Vusse, Van Faassen, Vardeny, Webb, Yin, Yusuf, Zamani, Zannad, Zannad, Zhang   +119 more
core   +1 more source

HIV positive patient with GBS-like syndrome [PDF]

, 2017
Introduction. Guillain–Barré Syndrome (GBS) is an acute demyelinating polyneuropathy which can occur post-infection. Criteria of diagnosis of GBS include areflexia with progressive bilateral weakness in arms and legs.
Black, Heather, Gunson, Rory N., Shepherd, Samantha J., Thomson, Emma C.   +3 more
core   +1 more source

Eplerenone for hypertension [PDF]

Cochrane Database of Systematic Reviews, 2011
Eplerenone is an aldosterone receptor blocker that is chemically derived from spironolactone. In Canada, it is indicated for use as adjunctive therapy to reduce mortality for heart failure patients with New York Heart Association (NYHA) class II systolic chronic heart failure and left ventricular systolic dysfunction.
Tina Sc, Tam, May Hy, Wu, Sarah C, Masson, Matthew P, Tsang, Sarah N, Stabler, Angus, Kinkade, Anthony, Tung, Aaron M, Tejani   +7 more
openaire   +2 more sources

Efficacy and safety of eplerenone treatment for patients with diabetic nephropathy: A meta-analysis

PLoS ONE, 2022
Diabetic nephropathy (DN), which is correlated with an increased risk of cardiovascular disease, significantly elevates the morbidity and mortality of patients with diabetes.
Honglei Hu, Xiaodong Zhao, Xingqian Jin, Shujuan Wang, Wen-Yih Liang, Xiangguo Cong   +5 more
semanticscholar   +1 more source